<DOC>
	<DOCNO>NCT00111800</DOCNO>
	<brief_summary>This 24-week study investigate safety efficacy several dosage potential new oral medicine Type II diabetes mellitus .</brief_summary>
	<brief_title>A New Oral Treatment For Type II Diabetes Mellitus</brief_title>
	<detailed_description>A 12-Week , Parallel-Group , Double-Blind , Randomized , Placebo-Controlled , Multicenter , Dose Ranging Study Evaluate Efficacy , Safety Tolerability GW823093 , Administered Orally , Once Daily , Monotherapy Subjects With Type 2 Diabetes Mellitus follow 12-week Active Treatment Extension</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Inclusion criterion : Women must pregnant must breastfeed . Have Type II diabetes . Not take medicine diabetes , take one oral medicine diabetes . Exclusion criterion : Have underlie significant active disease would prevent subject safely participate trial judgement study doctor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>NIDDM</keyword>
</DOC>